Important research results from five studies examining access to care and outcomes for patients living with pulmonary fibrosis and interstitial lung disease (ILD) are being presented at ATS 2022.
Medical Mutual of Ohio updated its coverage to include the Spiration Valve System for eligible patients suffering from severe emphysema.
Sometimes misdiagnosed as interstitial lung disease, hypersensitivity pneumonitis can be triggered by environmental allergens and causes inflammation of the lung tissue.
findings come from a study published in the American Journal of Preventive Medicine. Researchers tracked new lung disease among people who smoke and vape.
Read More
Pulmonary fibrosis (PF) is a complex interstitial lung disease that afflicts an estimated 100,000 Americans, with 30-40,000 new cases diagnosed each year.
Read More
The FDA has granted Ofev (nintedanib) a breakthrough therapy designation for chronic fibrosing interstitial lung disease, according to Boehringer Ingelheim.
Read More
The US FDA has approved Ofev (nintedanib) capsules to slow the rate of decline in pulmonary function in adults with interstitial lung disease associated with systemic sclerosis or scleroderma (SSc-ILD).
Read More
Ofev (nintedanib) reduced the annual rate of FVC decline in patients with systemic sclerosis associated interstitial lung disease (SSc-ILD).
Read More
Bayer Pharmaceuticals is terminating its Phase II study investigating riociguat in patients with pulmonary hypertension associated with idiopathic interstitial pneumonias.
Read More
Interstitial lung diseases (ILDs) comprise a spectrum of related disorders and correctly diagnosing and treating this diverse group is a challenge to clinicians.
Read More